Adam C. Lenain

Recent Representative Transactions

For Evofem Biosciences, Inc.

  • $80 million common stock PIPE with Woodford Investment Management and PDL Biopharma, Inc.

  • $100 million public offering underwritten by Morgan Stanley

  • $50 million ATM managed by Piper Sandler & Co.

  • Merger with Neothetics, Inc. (stock for stock)

  • $25 million senior secured convertible note PIPE with Baker Bros. 

  • $1 million preferred stock PIPE with Keystone Capital

  • $25 million unsecured convertible note PIPE with Adjuvant Global Health Technology Fund

  • $13.5 million registered direct offering conducted on a best efforts basis by Piper Sandler & Co.

  • $24 million public offering underwritten by H.C. Wainwright

For GRI Bio, Inc.

  • $12.5 million common stock PIPE with warrants with Altium Growth Fund

  • Merger with Vallon Pharmaceuticals (stock for stock)

  • $5 million public offering of common stock, pre-funded warrants and warrants to purchase preferred stock underwritten by AGP

  • ATM managed by H.C. Wainwright

For Wickr, Inc.

  • $8.3 million Series B-2 preferred stock financing led by Alsop Louie and Breyer Capital

  • $5 million Series C preferred stock financing led by Merlin International Inc.

  • $5 million venture debt financing with SVB

  • Merger with Net Power and Light (stock for stock)

Other Recent Financing Transactions

  • $3 million convertible note financing of Avenzoar Pharmaceuticals led by Ally Capital Holdings

  • $2 million Series A Preferred Stock financing of Curvo Labs, Inc. led by Snake Run Capital and Indiana 21st Century Fund

  • $18 million Series A Preferred Stock financing of FAScinate Therapeutics, Inc. led by Kainos Medicine and TWI IP Commercialization Fund and The Wells Doctors Healthcare Fund

  • $2 million convertible note financing of Hollywood Glow Girls

  • $2 million convertible note financing of Injury AI, Inc.

  • $1 million convertible note financing of Regencor, Inc.

Other Recent M&A Transactions

  • Curvo Labs, Inc. stock purchase of Mendenhal Associates (cash consideration)

  • Curvo Labs, Inc. stock purchase of Strategic Healthcare (cash consideration)

  • Evofem, Inc.’s asset purchase of Cosmederm, Inc. (cash consideration)

  • Encore Sports asset sale to Decade Sports (cash consideration)

  • Evanoa Bioscience, Inc. asset acquisition of Evolugate LLC (stock consideration)

  • Evanoa Bioscience, Inc. asset acquisition of Biotork LLC (stock consideration)

Commercial Agreements

  • License Agreement between NeptuneBio, Inc. and Mayo Clinic

  • Development Agreement between Evanoa Bioscience and Aldevron

  • Multiple Consulting Agreement and Employment Agreements

  • License Agreement between Avenzoar Pharmaceuticals and Cedars-Sinai

  • Development Agreement between Biotork LLC and Lallemand/Mascoma

  • Joint Venture Agreement between Caelum Resources, Inc. and CFS Holdings Private Limited Zimbabwe

  • Multiple SAAS Agreements for Curvo Labs, Inc. and Wickr Inc.

  • License Agreement between FAScinate Therapeutics and Kainos Medicine

  • License Agreement between InVaMet and Virginia Commonwealth

  • License Agreement between ILCT and Virginia Commonwealth

Evofem Biosciences Closes $25M PIPE Case Study

Evofem Biosciences Closes $25M PIPE

After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.